Senior Clinical Research Fellow
Parminder K Judge is a Senior Clinical Research Fellow based in the Renal Studies Group at the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU).
Parminder studied medicine at the University of Birmingham. After completing her core medical training in Leicester, she undertook specialty training in nephrology in the Oxford rotation. In 2013, she took time ‘out-of-programme for research’ to work on clinical trials. She worked primarily on the UK HARP-III trial which compared the effects of sacubitril/valsartan (a novel angiotensin-receptor neprilysin inhibitor) with irbesartan (an angiotensin receptor blocker) on in 400 people with chronic kidney disease. The trial formed the basis of her PhD thesis.
She also undertook the adjudication of clinical outcomes for the 3C trial and provided clinical support for the REVEAL and ASCEND trials. She participated in epidemiological analyses of the SHARP trial assessing the effects of blood pressure on cardiovascular outcomes. Parminder used HES data to establish and quantify previously undocumented hepatorenal complications in polycystic kidney disease and, to determine the risk of many established complications of the disease.
After completing her nephrology specialty training in 2020, Parminder returned to CTSU to work on clinical trials in nephrology and cardiovascular disease, including the EMPA-KIDNEY trial. She now aims to develop her knowledge and experience of clinical trials, testing new treatments aimed at managing and reducing the progression of chronic kidney disease.
She continues to practice nephrology within the Oxford Kidney Unit and has an active interest in teaching clinical trainees, undergraduate and postgraduate students.
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Zhu D. et al, (2024), Am J Kidney Dis
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology